Pulmonary epithelioid inflammatory myofibroblastic sarcoma with multiple bone metastases: case report and review of literature by Xinge Fu et al.
CASE REPORT Open Access
Pulmonary epithelioid inflammatory
myofibroblastic sarcoma with multiple bone
metastases: case report and review of literature
Xinge Fu1, Juhong Jiang1, Xiao-ying Tian2 and Zhi Li3*
Abstract
Epithelioid inflammatory myofibroblastic sarcoma (EIMS) is a rare variant of inflammatory myofibroblastic tumor
with distinctive morphological features and malignant clinical behavior. Only a few such cases have been described
in the literature. We report here a case of unusual pulmonary EIMS with multiple bone metastases. A 21-year-old
Chinese male patient presented with complaints of general fatigue and rapid weight loss, and a huge tumor arising
in the left lower lobe of lung was detected by chest computed tomography. The mass of lung was totally resected.
Microscopically, the tumor cells were rounded and epithelioid in shape. Myxoid stroma and inflammatory infiltration
was also present. The tumor cells were immunopositive to anaplastic lymphoma kinase (ALK) in smooth
cytoplasmic pattern. Fluorescence in situ hybridization (FISH) assay revealed the presence of rearrangement of ALK
gene. Three months after lung surgery, there were multiple bone metastases and intraspinal mass found by
positron emission tomography. The second surgical treatment was performed to remove the intraspinal lesion. The
histological and immunohistochemical features of intraspinal mass were similar to those of pulmonary tumor. The
diagnosis of pulmonary EIMS with multiple bone metastases was made. To the best of our knowledge, it may be
the first case of an EIMS arising in lung. Awareness of EIMS in respiratory tract and its distinctive features is
important for pathologists to avoid a diagnostic pitfall caused by histologic similarities to other ALK-positive tumors.
ALK inhibitor is a promising treatment for this aggressive tumor regardless of its potential acquired resistance.
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Background
Inflammatory myofibroblastic tumor (IMT) is a mes-
enchymal neoplasm of intermediate biological poten-
tial, which frequently occur in the lung or abdominal
cavity of children and young adults. Its clinical course
is relatively indolent, but may recur and rarely
metastasize [1]. Recently, a rare variant of IMT with dis-
tinct morphological and immunohistochemical features,
epithelioid inflammatory myofibroblastic sarcoma (EIMS),
has been described by Marino-Enriquez et al. in 2011 [2].
Histologically, EIMS is characterised by epithelioid
morphology and a nuclear membrane or perinuclear pat-
tern of immunostaining for anaplastic lymphoma kinase
(ALK), and Ran-binding protein 2 (RANBP2)-ALK fusion
in genetic examination. Unlike conventional IMT, EIMS
carries poor prognosis and is associated with rapid devel-
opment of local recurrence [1, 2]. To the best of our
knowledge, so far only 13 cases of EIMS have been de-
scribed in the literature, and only a few cases show the dis-
tant metastasis [2–4]. Herein, we present an unusual
pulmonary EIMS with multiple bone metastases occurring
in a young male patient. It may be the first case of an
EIMS arising in the lung. Due to its rarity, the clinical and
histological features of this tumor, as well as differential
diagnosis are discussed.
Case presentation
Clinical manifestation and management
A 21-year-old non-smoking young man presented with
complaints of general fatigue and rapid weight loss in
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the past 3 months. During this period, he was referred
to a local hospital for radiological examination. Com-
puted tomographic (CT) scans revealed a huge mass in
the left lung. A fibreoptic bronchoscopy was performed
in the local hospital, but biopsy examination was nega-
tive because only inflammatory mucosa was observed
under the microscopy. As a result, the patient was re-
ferred to our hospital for examination and treatment.
Physical examination results were normal. The labora-
tory results, including blood count, serum tumor
markers and liver and renal function, were within the
normal range. The CT images acquired at the local
hospital showed a 10.0 × 8.0 cm well-circumscribed
mass in the left lower lobe of lung without signs of
neighboring pleura invasion (Fig. 1a and b). There
was no enlarged lymph node of the pleural cavity
found. Whole body F18-fluorodeoxyglucose (FDG)
positron emission tomography (PET)/CT study was
not preformed at that time because there was no sign
of tumor distant metastasis. Since the patient was a
young adult, the preoperative impression of the lesion
was a mesenchymal sarcoma of lung. The patient
underwent a left lobe-ectomy of lung, and the mass
was gross totally resected. Postoperative recovery was
uneventful without surgical complications. After diag-
nosis, the patient received Crizotinib, an oral anaplas-
tic lymphoma kinase inhibitor, at a dose of 250 mg
twice daily. However, the patient rapidly presented
back pain and left lower limb dysfunction at the third
month after pulmonary surgery. The patient was then
referred to a whole body PET/CT study to search for
the potentially secondary tumor. PET/CT revealed
that multiple abnormally increased FDG uptake was
found in pelvic bone and vertebra. An intraspinal
mass at T10 was also observed (Fig. 1c and d). A sec-
ond laminectomy was performed under the impres-
sion of tumor metastasis, and the majority of the
intraspinal mass was resected. However, the patient
developed persistent fever and cachexia. Finally, he
died 4 months after the initial pulmonary surgery.
Fig. 1 Radiological findings of lung tumor and metastatic lesions of bone. a Chest computed tomography (CT) revealed a huge well-
circumscribed mass in the left lower lobe of lung without signs of neighboring pleura invasion (white arrow). b The pulmonary tumor showed
heterogeneous enhancement. Three months after surgery, F18-fluorodeoxyglucose (FDG) positron emission tomography revealed abnormally
increased FDG uptake in the pelvic bone (c) and vertebra mass (d) (white arrows), indicating metastatic lesions of bones
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Pathological findings
The surgical specimens was received and routinely fixed
in 10 % neutral buffered formalin after tumor resection.
Four micrometer thick sections were cut and stained
with H&E. On microscopic examination, the pulmonary
and intraspinal masses exhibited similar histological ap-
pearance. Both tumors were non-encapsulated and had
an infiltrative margin. The pulmonary tumor was com-
posed of two areas with distinct histological appearance.
In one area, the interlacing bundles of spindle cells were
found to intermingle with plasma cells and lymphocytes.
The plump polygonal-like myofibroblasts with promin-
ent nucleoli were also observed in myxoid background.
The microscopical appearance of this area was consist-
ent with the histological features of conventional IMT
(Fig. 2a-c). However, in other area, the tumor was com-
posed of diffused well-circumscribed polygonal and epi-
thelioid tumor cells with distinct nucleoli and eosinophilic
or pale cytoplasm. Nuclear atypia, mitotic figures (3/10
high power field) and focal necrosis were observed. Back-
ground of tumor in this area showed myxoid change with
inflammatory cells infiltration, mainly neutrophils, eosino-
phils and lymphocytes. The intraspinal tumor was com-
posed of only polygonal and epithelioid tumor cells. The
spindle cell component was not present in intraspinal
tumor (Fig. 2d-f).
Fig. 2 Postoperative micrographs of pulmonary and intraspinal masses. a Pulmonary tumor was non-encapsulated and observed to infiltrating
the surrounding lung tissue. b In some areas of pulmonary tumor, the interlacing bundles of spindle cells were found to intermingle with plasma
cells and lymphocytes. c The plump polygonal-like myofibroblasts with prominent nucleoli were also observed in myxoid background. d In other
areas, the tumor was composed of diffused well-circumscribed polygonal and epithelioid tumor cells with distinct nucleoli. Nuclear atypia and
mitotic figures were observed. e Necrosis could be found in epithelioid areas of pulmonary tumor. f The intraspinal tumor was composed of only
polygonal and epithelioid tumor cells. a HE staining with original magnification × 100; b-f, HE staining with original magnification × 400)
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Immunohistochemical and FISH findings
Immunohistochemically, the tumor cells in both messes
were positive for vimentin and desmin diffusely. They
were negative for Pan-CK (AE1/AE3), smooth muscle
actin (SMA), HHF35, myogenin, Myo D1, S100, HMB45,
Melan A, synaptophysin, CD34, CD68 and CD30. In
addition, the tumor cells were positive for ALK, exhibit-
ing a cytoplasmic pattern (Fig. 3a-e). The rearrangement
of the ALK gene at chromosome band 2p23 was detected
by fluorescence in situ hybridization (FISH) utilizing Vysis
ALK break apart probe (Vysis, Abbott Laboratories Inc.,
Maidenhead, UK). FISH analysis showed rearrangement
of ALK present in both pulmonary and intraspinal
masses (Fig. 3f ).
On the basis of gross, histopathological features and
immunohistochemical phenotypes, its epithelioid morph-
ology and myxoid background, the presence of inflam-
matory infiltrating and ALK cytoplasmic positive signal
pattern, a diagnosis of epithelioid inflammatory myofi-
broblastic sarcoma (EIMS) with multiple bone metasta-
ses was made.
Discussion
EIMS is proposed as a rare variant of IMT and has firstly
been designated by Marino-Enriquez et al. in 2011 be-
cause of its malignant clinical behavior [2]. Unlike con-
ventional IMT, EIMS is characterized by plump round-to-
epithelioid tumor cells embedding in abundant myxoid
Fig. 3 Immunohistochemical and FISH assay of tumor. The polygonal and epithelioid tumor cells were observed to be positive for Desmin
diffusely (a) and ALK in smooth cytoplasmic pattern (b). c The spindle cells in pulmonary tumor were also found to be positive for ALK. However,
the epithelioid tumor cells were negative for CD30 (d) and SMA (e) staining. f FISH assay with break-apart probe for ALK gene shows one intact
yellow signal, one separated red and green signal per nucleus in tumor cells indicating the presence of a rearrangement of ALK gene.
(a-e, immunohistochemical staining with original magnification × 400; f, FISH assay with original magnification × 400)
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stroma with inflammatory infiltrate, as well as immunopo-
sitivity for ALK, and frequent RANBP2-ALK fusion gene.
In 2013, the latest edition of World Health Organization
(WHO) tumor classification of soft tissue (4th edition) has
accepted EIMS as a variant of IMT, and identified it “seems
to portend more aggressive clinical behavior”, which fur-
ther indicates malignant nature of this tumor, although
most of conventional IMT has relatively indolent clinical
course with low rate of metastasis [1].
Since its first description by Marino-Enriquez et al. so
far only 13 such cases have been described in the litera-
ture (Table 1) [2–4]. Of these 3 were children and 10
were adults with obvious male predilection, only 1 case
occurred in female patient. The age range for all reported
cases is from 7 months to 63 years (mean age 33y). Al-
most all of tumors were intra-abdominal, including the
mesentery of the small bowel, omentum and peritoneum.
Only 1 case arises from pleural cavity [3]. To the best of
our knowledge, our case is the first case of primary pul-
monary EIMS. Clinically, EIMS presents as a rapid grow-
ing intra-abdominal mass or pleural cavity nodule, it
usually comes to medical attention when presence of ab-
dominal pain, ascites or pleural effusion. Cases of reported
EIMS have ranged in size from 6 to 26 cm [2–4]. In the
present case, general fatigue and weight loss pain is the
primary clinical manifestation instead of abdominal pain
and a palpable nodular lesion.
Since cases of EIMS are so rare, the diagnosis should
be only made by strict histological and clinical manifest-
ation. Based on the previously reported cases, the com-
mon histological features of EIMS are plump round-to-
epithelioid cell morphology and abundant myxoid
stroma with inflammatory infiltrating. Immunopositivity
for ALK consistently and CD30 frequently has also been
identified in most of cases [2–4]. However, these criteria
can differentiate this neoplasm from epithelial-origin tu-
mors, the same criteria could not differentiate the lesion
from several mesenchymal tumors, especially from
extra-nodular anaplastic large cell lymphoma (ALCL).
The differential diagnosis between EIMS and ALCL can
be particularly difficult, especially considering that the
rare sarcomatoid variant of ALCL can show spindle cell
morphology and an overlapping immunophenotype of
ALK, CD30 positive staining, and SMA, EMA negative
staining [5]. However, diffuse expression of Desmin in
tumor cells have demonstrated in all reported cases, in-
cluding our presenting case, which is not seen in ALCL.
Moreover, there are three ALK staining patterns: dis-
tinctive nuclear membrane staining, granular cytoplas-
mic staining and smooth cytoplasmic staining, as seen in
the present case. Some researchers suggest that these
staining patterns are associated with RANBP2-ALK,
CLTC-ALK and TPM3/4-ALK fusion partner, respect-
ively [6]. The RANBP2-ALK fusion is considered specific
to EIMS and has not been reported in ALCL. Therefore,
the distinctive nuclear membrane pattern of ALK stain-
ing may be useful for differential diagnosis of these two
tumors. The differential diagnosis with the solid variant
of alveolar rhabdomyosarcoma, especially those exam-
ples showing ALK-positive, can also be difficult [7].
However, absence of myxoid stroma and inflammatory
infiltrating, and nuclear immunoreactivity for myo-
genin and Myo-D1 are helpful to confirm the diagno-
sis of rhabdomyosarcoma.
In our case, ALK rearrangement has been confirmed
by FISH assay. However, certain ALK gene fusions can
not be identified unless more sensitive molecular tech-
nique, such as PCR assay or gene sequencing is per-
formed for that detection. In fact, various partner genes
have been identified to fuse with 3′kinase region of ALK
gene. Nucleophosmin (NPM)-ALK fusion occurring
ALCLs has been reported to be detected in approxi-
mately 50 % of IMTs [8]. Besides RANBP2, tropomyosin
3 (TPM3) and tropomyosin 4 (TPM4), clathrin heavy
chain (CLTC), cysteinyl-tRNA synthetase (CARS), 5-
aminoimidazole-4-carboxamide ribonucleotide formyl-
transferase/IMP cyclohydrolase (ATIC) and SEC31L1
have also been identified to fuse with ALK gene, and
provide active promoters for the fusion gene [9–12].
Several reports have suggested that IMTs with RANBP2-
ALK fusion usually exhibit an epithelioid/round cell
morphology and follow a more aggressive clinical
course [13, 14]. Recently, echinoderm microtubule-
associated protein-like 4 (EML4)-ALK fusion and vin-
culin (VCL)-ALK fusion have also been identified in
non-small cell lung cancer (NSCLC) [15] and renal
cell carcinoma [16], respectively, which has not been
described in IMT or EIMS yet. It has proposed that
these tumors be collectively referred to as “ALKoma”,
in which ALK genetic changes play essential roles in
carcinogenesis [17].
The EIMS appears to have a poor prognosis with short
survival time after surgical treatment and following
chemotherapy and /or radiotherapy. Among those re-
ported cases, 5 patients died within 3 to 36 months after
the initial diagnosis, and 9 patients occurs local tumor
recurrence and 3 patients had distant metastasis [2–4].
Our patient survived for only 4 months after aggressive
surgical intervention and administration of crizotinib.
The effectiveness of alternative treatment modalities
such as radiotherapy, chemotherapy, and steroids is un-
certain [18, 19]. Because EIMS frequently contain a rear-
ranged ALK gene, ALK inhibitors are theoretically useful
for treating these tumors, regardless of the site of origin.
Butrynski et al. reported a case of IMT in a patient with
the RANBP2-ALK fusion gene who was treated with the
ALK inhibitor crizotinib after surgical tumor resection,
in which 19 months have passed without evidence of
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Table 1 Clinicopathological features of EIMSs described in present and previous reports




Immuno-phenotype Molecular change Recurrence Metastasis Treatment Outcome
1 Marino-Enriquez
A (2011) [2]
59/Male Mesentery/15.0 Abdominal pain
and/or ascites
Des+, SMA+, ALK+(N) ALK-rearrangement (FISH) Yes None SE + CT DOD 12 months
after SE
2 41/Male Omentum/26.0 Des+,CD30+, ALK+(N) ALK-rearrangement (FISH)/
RANBP2 -ALK fusion (PCR)




3 6/Male Omentum/10.5 Des+, SMA-, ALK+(N) ALK-rearrangement (FISH) Yes None SE + CT AWD 13 months
after SE
4 28/Male Mesentery/NA Des+, SMA+, ALK+(N) NA NA NA NA NA




Des+, ALK+(N) NA Yes None SE + CT AWD 13 months
after SE










9 31/Female Mesentery/17.5 Des+,CD30+, ALK+(N) ALK-rearrangement (FISH) Yes None SE + CT DOD 11 months
after SE
10 6/Male Omentum and
mesentery/14.0
Des+,CD30+, ALK+(N) ALK-rearrangement (FISH)/
RANBP2 -ALK fusion (PCR)
NA NA SE NA
11 39/Male Mesentery/15.0 Des+,CD30+, ALK+(N) ALK-rearrangement (FISH)/
RANBP2 -ALK fusion (PCR)
NA NA SE NA




RANBP2-ALK fusion (PCR) NA NA Biopsy +
ALKi
NA
13 Kimbara S (2014)
[4]
22/Male Pelvis/6.0 Fever, fatigue,
abdominal pain






14 Present case 21/Male Lung/10.0 Fatigue and
weight loss






SE surgical excision, CT chemotherapy, RT radiotherapy, DOD dead of disease, ANED alive, no evidence of disease, AWD alive with disease, NA data not available, Vim Vimentin, Des Desmin, ALK anaplastic lymphoma











recurrence [20]. Kurihara-Hosokawa [21] and Fujiya [22]
recently have also presented a patient with recurred
EIMS continues to be alive with disease 14 months after
surgical treatment and the administration of the ALK in-
hibitor crizotinib. Therefore, some researchers suggest
that treatment with surgery and the ALK inhibitor crizo-
tinib may become the standard treatment for EIMS that
is positive for the RANBP2-ALK fusion gene [21]. How-
ever, acquired resistance of ALK inhibitor crizotinib
seems to be unavoidable. In NSCLC, ALK-positive pa-
tients develop disease progression after receiving crizo-
tinib for 8–10 months [23]. Sasaki et al. reported IMT
with RANBP2-ALK fusion gene acquired resistance to cri-
zotinib because of secondary F1174L ALK mutation [24].
The F1174L is also found in crizotinib resistant NSCLC
model [25]. The novel agents need to overcome acquired
resistance to crizotinib in EIMS.
Conclusion
In conclusion, we encountered an unusual case of pul-
monary EIMS with rapidly lethal clinical course. To the
best of our knowledge, it may be the first case of EIMS
originating in the lung with multiple bone metastases.
Due to its rarity, the diagnosis of EIMS, especially occur-
ring in unusual sites, is difficult and should be made
cautiously. Awareness of EIMS in respiratory tract and
its distinctive features is important for pathologists to
avoid a diagnostic pitfall caused by histologic similarities
to other ALK-positive tumors. RANBP2-ALK fusion
likely plays the essential role in the carcinogenesis of this
tumor, and ALK inhibitor is a promising treatment for
this aggressive tumor regardless of its potential acquired
resistance.
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